{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:22:38Z","timestamp":1786112558276,"version":"build-2736575974"},"reference-count":147,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Plain balloon angioplasty was the initial method used to enlarge the intracoronary lumen size. However, it was linked to acute coronary closure due to early vessel recoil. This led to the invention of coronary stents, which offer mechanical support to open and maintain the vascular lumen. Nevertheless, the metallic scaffold introduced other issues, such as thrombosis and restenosis caused by neointimal proliferation. To address these concerns, polymers were employed to cover the scaffold, acting as drug reservoirs and regulators for controlled drug release. The use of polymers prevents direct contact between blood and metallic scaffolds. Drugs within the stent were incorporated to inhibit proliferation and expedite endothelialization in the healing process. Despite these advancements, adverse effects still arise due to the inflammatory reaction caused by the polymer material. Consequently, resorbable polymers and scaffolds were later discovered, but they have limitations and are not universally applicable. Various scaffold designs, thicknesses, materials, polymer components, and drugs have their own advantages and complications. Each stent generation has been designed to address the shortcomings of the preceding generation, yet new challenges continue to emerge. Conflicting data regarding the long-term safety and efficacy of coronary stents, especially in the extended follow-up, further complicates the assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/crd.0000000000000705","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T09:07:55Z","timestamp":1714986475000},"page":"397-407","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Revolutionizing Cardiovascular Frontiers: A Dive Into Cutting-Edge Innovations in Coronary Stent Technology"],"prefix":"10.1097","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0310-3382","authenticated-orcid":false,"given":"Alice Valeria","family":"Wiyono","sequence":"first","affiliation":[{"name":"Faculty of Life Sciences & Medicine, King\u2019s College London, School of Cardiovascular and Metabolic Medicine, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0250-0090","authenticated-orcid":false,"given":"Azizah Puspitasari","family":"Ardinal","sequence":"additional","affiliation":[{"name":"Faculty of Life Sciences & Medicine, King\u2019s College London, School of Cardiovascular and Metabolic Medicine, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(78)90500-7","article-title":"Transluminal dilatation of coronary-artery stenosis.","volume":"311","author":"Gr\u00fcntzig","year":"1978","journal-title":"Lancet"},{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0008-6363(96)00038-7","article-title":"Mechanisms and prevention of restenosis: from experimental models to clinical practice.","volume":"31","author":"Bauters","year":"1996","journal-title":"Cardiovasc Res"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM199408253310802","article-title":"A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease.","volume":"331","author":"Fischman","year":"1994","journal-title":"N Engl J Med"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199408253310801","article-title":"A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease.","volume":"331","author":"Serruys","year":"1994","journal-title":"N Engl J Med"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM199101033240103","article-title":"Angiographic follow-up after placement of a self-expanding coronary-artery stent.","volume":"324","author":"Serruys","year":"1991","journal-title":"N Engl J Med"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","article-title":"Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.","volume":"349","author":"Moses","year":"2003","journal-title":"N Engl J Med"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa032441","article-title":"A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.","volume":"350","author":"Stone","year":"2004","journal-title":"N Engl J Med"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.biomaterials.2006.11.042","article-title":"Coronary stents: a materials perspective.","volume":"28","author":"Mani","year":"2007","journal-title":"Biomaterials"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"e000680","DOI":"10.1136\/openhrt-2017-000680","article-title":"Long and short of optimal stent design.","volume":"4","author":"Watson","year":"2017","journal-title":"Open Heart"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/136457002760273386","article-title":"A comparison of balloon-and self-expanding stents.","volume":"11","author":"Duerig","year":"2002","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"R12-20260805","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/bmb\/ldt009","article-title":"Coronary stents: historical development, current status and future directions.","volume":"106","author":"Iqbal","year":"2013","journal-title":"Br Med Bull"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"89","DOI":"10.15420\/icr.2011.9.2.89","article-title":"Clinical impact of stent design.","volume":"9","author":"Noad","year":"2014","journal-title":"Interv Cardiol"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1161\/01.CIR.0000019071.72887.BD","article-title":"Morphological predictors of restenosis after coronary stenting in humans.","volume":"105","author":"Farb","year":"2002","journal-title":"Circulation"},{"key":"R15-20260805","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1054-8807(03)00132-7","article-title":"Pathological analyses of long-term intracoronary Palmaz\u2013Schatz stenting: is its efficacy permanent?","volume":"13","author":"Inoue","year":"2004","journal-title":"Cardiovasc Pathol"},{"key":"R16-20260805","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/CIRCULATIONAHA.116.023681","article-title":"The birth, and evolution, of percutaneous coronary interventions: a conversation with Patrick Serruys, MD, PhD.","volume":"134","author":"Serruys","year":"2016","journal-title":"Circulation"},{"key":"R17-20260805","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1161\/01.CIR.94.5.882","article-title":"Intracoronary stenting: from concept to custom.","volume":"94","author":"Ruygrok","year":"1996","journal-title":"Circulation"},{"key":"R18-20260805","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jcp.2004.024174","article-title":"Coronary artery stents: identification and evaluation.","volume":"58","author":"Butany","year":"2005","journal-title":"J Clin Pathol"},{"key":"R19-20260805","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/eurheartj\/ehl282","article-title":"Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis.","volume":"27","author":"Nordmann","year":"2006","journal-title":"Eur Heart J"},{"key":"R20-20260805","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","article-title":"Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.","volume":"370","author":"Stettler","year":"2007","journal-title":"Lancet"},{"key":"R21-20260805","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacc.2010.06.007","article-title":"Coronary stents: current status.","volume":"56","author":"Garg","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R22-20260805","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.amjcard.2016.06.061","article-title":"Trends in bare-metal stent use in the United States in patients aged\u2265 65 years (from the CathPCI Registry).","volume":"118","author":"Rymer","year":"2016","journal-title":"Am J Cardiol"},{"key":"R23-20260805","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/jamacardio.2018.3573","article-title":"The myths of the bare-metal stent.","volume":"3","author":"Kereiakes","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R24-20260805","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jacc.2012.11.049","article-title":"Why are we still using coronary bare-metal stents?","volume":"61","author":"Morice","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R25-20260805","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R26-20260805","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.carrev.2014.12.007","article-title":"Primary endpoint results of the OMEGA study: one-year clinical outcomes after implantation of a novel platinum chromium bare metal stent.","volume":"16","author":"Wang","year":"2015","journal-title":"Cardiovasc Revasc Med"},{"key":"R27-20260805","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1615\/JLongTermEffMedImplants.v10.i12.120","article-title":"Influence of topography on endothelialization of stents: clues for new designs.","volume":"10","author":"Simon","year":"2000","journal-title":"J Long Term Eff Med Implants"},{"key":"R28-20260805","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2003.10.049","article-title":"Impact of strut thickness on late luminal loss after coronary artery stent placement.","volume":"93","author":"Rittersma","year":"2004","journal-title":"Am J Cardiol"},{"key":"R29-20260805","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1161\/01.CIR.103.23.2816","article-title":"Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial.","volume":"103","author":"Kastrati","year":"2001","journal-title":"Circulation"},{"key":"R30-20260805","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0735-1097(03)00119-0","article-title":"Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial.","volume":"41","author":"Pache","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R31-20260805","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2015.04.017","article-title":"Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.","volume":"65","author":"Palmerini","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R32-20260805","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1161\/01.CIR.0000069330.41022.90","article-title":"New frontiers in cardiology: drug-eluting stents: Part I.","volume":"107","author":"Sousa","year":"2003","journal-title":"Circulation"},{"issue":"10S","key":"R34-20260805","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2010.06.008","article-title":"Coronary stents: looking forward.","volume":"56","author":"Garg","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R35-20260805","doi-asserted-by":"crossref","first-page":"e002943","DOI":"10.1161\/CIRCINTERVENTIONS.115.002943","article-title":"Stent polymers: do they make a difference?","volume":"9","author":"Rizas","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"R36-20260805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13019-022-01812-y","article-title":"Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach.","volume":"17","author":"Hassan","year":"2022","journal-title":"J Cardiothorac Surg"},{"key":"R37-20260805","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/01.CIR.0000047700.58683.A1","article-title":"TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions.","volume":"107","author":"Grube","year":"2003","journal-title":"Circulation"},{"key":"R38-20260805","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1161\/CIRCULATIONAHA.109.849877","article-title":"Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions.","volume":"120","author":"Silber","year":"2009","journal-title":"Circulation"},{"key":"R39-20260805","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1161\/01.CIR.0000048184.96491.8A","article-title":"TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation.","volume":"107","author":"Tanabe","year":"2003","journal-title":"Circulation"},{"key":"R40-20260805","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/01.CIR.0000127110.49192.72","article-title":"One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.","volume":"109","author":"Stone","year":"2004","journal-title":"Circulation"},{"key":"R41-20260805","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jacc.2005.11.077","article-title":"Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial.","volume":"47","author":"Weisz","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R42-20260805","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/01.CIR.0000025585.63486.59","article-title":"Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial.","volume":"106","author":"Serruys","year":"2002","journal-title":"Circulation"},{"key":"R43-20260805","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jama.295.8.895","article-title":"Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.","volume":"295","author":"Morice","year":"2006","journal-title":"JAMA"},{"key":"R44-20260805","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(04)17275-9","article-title":"Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.","volume":"364","author":"McFadden","year":"2004","journal-title":"Lancet"},{"key":"R45-20260805","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/CIRCULATIONAHA.106.666800","article-title":"Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern.","volume":"115","author":"Camenzind","year":"2007","journal-title":"Circulation"},{"key":"R46-20260805","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1161\/CIRCULATIONAHA.107.688416","article-title":"Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7\u20138, 2006.","volume":"115","author":"Laskey","year":"2007","journal-title":"Circulation"},{"key":"R47-20260805","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1161\/CIRCULATIONAHA.106.675934","article-title":"Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.","volume":"115","author":"Luscher","year":"2007","journal-title":"Circulation"},{"key":"R48-20260805","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.107.730010","article-title":"Comparison of inflammatory response after implantation of sirolimus-and paclitaxel-eluting stents in porcine coronary arteries.","volume":"120","author":"Wilson","year":"2009","journal-title":"Circulation"},{"key":"R49-20260805","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings.","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"key":"R50-20260805","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1067\/mva.2002.129113","article-title":"Influence of stent design and material composition on procedure outcome.","volume":"36","author":"Palmaz","year":"2002","journal-title":"J Vasc Surg"},{"key":"R51-20260805","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/ehjci\/jes025","article-title":"Optical coherence tomography: from research to practice.","volume":"13","author":"Gutierrez-Chico","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R52-20260805","doi-asserted-by":"crossref","first-page":"e008024","DOI":"10.1161\/CIRCINTERVENTIONS.119.008024","article-title":"Long-term effect of ultrathin-strut versus thin-strut drug-eluting stents in patients with small vessel coronary artery disease undergoing percutaneous coronary intervention: a subgroup analysis of the BIOSCIENCE randomized trial.","volume":"12","author":"Iglesias","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"R55-20260805","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","article-title":"Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.","volume":"17","author":"MacKeigan","year":"2015","journal-title":"Neuro-Oncology"},{"key":"R56-20260805","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1517\/14656566.2014.948844","article-title":"Pharmacological inhibition of coronary restenosis: systemic and local approaches.","volume":"15","author":"Guerra","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"R57-20260805","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jcin.2010.06.010","article-title":"Thrombosis of second-generation drug-eluting stents in real practice: results from the multicenter Spanish registry ESTROFA-2 (Estudio Espa\u00f1ol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2).","volume":"3","author":"de la Torre Hern\u00e1ndez","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"R58-20260805","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1004130","article-title":"Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.","volume":"363","author":"Serruys","year":"2010","journal-title":"N Engl J Med"},{"key":"R59-20260805","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(11)60395-4","article-title":"Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial.","volume":"377","author":"Silber","year":"2011","journal-title":"Lancet"},{"key":"R60-20260805","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.jacc.2006.08.035","article-title":"Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.","volume":"48","author":"Kandzari","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R61-20260805","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jcin.2010.12.014","article-title":"Late-term clinical outcomes with zotarolimus-and sirolimus-eluting stents: 5-year follow-up of the ENDEAVOR III (A randomized controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions).","volume":"4","author":"Kandzari","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"R62-20260805","first-page":"286","article-title":"A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial.","volume":"2","author":"Serruys","year":"2006","journal-title":"EuroIntervention"},{"key":"R63-20260805","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4244\/EIJV8I9A161","article-title":"Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.","volume":"8","author":"Onuma","year":"2013","journal-title":"EuroIntervention"},{"key":"R64-20260805","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.299.16.1903","article-title":"Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.","volume":"299","author":"Stone","year":"2008","journal-title":"JAMA"},{"key":"R65-20260805","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.amjcard.2010.10.069","article-title":"Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial).","volume":"107","author":"Applegate","year":"2011","journal-title":"Am J Cardiol"},{"key":"R66-20260805","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(10)60208-5","article-title":"Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.","volume":"375","author":"Rasmussen","year":"2010","journal-title":"Lancet"},{"key":"R67-20260805","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jcin.2012.04.008","article-title":"3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus-and sirolimus-eluting coronary stents.","volume":"5","author":"Maeng","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"R68-20260805","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jacc.2009.08.067","article-title":"A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions: 12-month outcomes from the ENDEAVOR IV trial.","volume":"55","author":"Leon","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R69-20260805","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcin.2012.12.123","article-title":"The \u201cfinal\u201d 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.","volume":"6","author":"Kirtane","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"R70-20260805","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jacc.2010.03.086","article-title":"Comparison of zotarolimus-eluting stents with sirolimus-and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial.","volume":"56","author":"Park","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R71-20260805","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(09)62127-9","article-title":"Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.","volume":"375","author":"Kedhi","year":"2010","journal-title":"Lancet"},{"key":"R72-20260805","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jacc.2011.02.023","article-title":"2-year follow-up of a randomized controlled trial of everolimus-and paclitaxel-eluting stents for coronary revascularization in daily practice: COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERT\u00c9 stent in all-comers: a randomized open label trial).","volume":"58","author":"Smits","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R73-20260805","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0910496","article-title":"Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.","volume":"362","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"R74-20260805","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacc.2011.02.022","article-title":"Randomized comparison of everolimus-and paclitaxel-eluting stents: 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.","volume":"58","author":"Stone","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R75-20260805","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/eurheartj\/ehp044","article-title":"A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.","volume":"30","author":"Byrne","year":"2009","journal-title":"Eur Heart J"},{"key":"R76-20260805","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1161\/CIRCULATIONAHA.111.063644","article-title":"Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV).","volume":"125","author":"Jensen","year":"2012","journal-title":"Circulation"},{"key":"R77-20260805","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jacc.2012.07.004","article-title":"2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial.","volume":"60","author":"Jensen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R78-20260805","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jacc.2015.11.051","article-title":"Safety and efficacy of everolimus-versus sirolimus-eluting stents: 5-year results from SORT OUT IV.","volume":"67","author":"Jensen","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R79-20260805","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/CIRCULATIONAHA.112.104059","article-title":"Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET).","volume":"126","author":"Kimura","year":"2012","journal-title":"Circulation"},{"key":"R80-20260805","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1093\/eurheartj\/ehu318","article-title":"Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial.","volume":"35","author":"Wijns","year":"2014","journal-title":"Eur Heart J"},{"key":"R81-20260805","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0142-9612(01)00297-6","article-title":"Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre-and post-implantation.","volume":"23","author":"Lewis","year":"2002","journal-title":"Biomaterials"},{"key":"R83-20260805","first-page":"53","article-title":"Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating.","volume":"1","author":"Grube","year":"2005","journal-title":"EuroIntervention"},{"key":"R84-20260805","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(08)61244-1","article-title":"Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.","volume":"372","author":"Windecker","year":"2008","journal-title":"Lancet"},{"key":"R85-20260805","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(11)61672-3","article-title":"Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.","volume":"378","author":"Stefanini","year":"2011","journal-title":"Lancet"},{"key":"R86-20260805","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)61852-2","article-title":"Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.","volume":"381","author":"Smits","year":"2013","journal-title":"Lancet"},{"key":"R87-20260805","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jcin.2017.02.029","article-title":"Biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: final 5-year report from the COMPARE II trial (abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent).","volume":"10","author":"Vlachojannis","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"R88-20260805","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/eurheartj\/ehu210","article-title":"A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial.","volume":"35","author":"Saito","year":"2014","journal-title":"Eur Heart J"},{"key":"R89-20260805","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.4244\/EIJ-D-18-00358","article-title":"Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: final five-year results of the CENTURY II randomised clinical trial.","volume":"14","author":"Wijns","year":"2018","journal-title":"EuroIntervention"},{"key":"R90-20260805","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(14)61038-2","article-title":"Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.","volume":"384","author":"Pilgrim","year":"2014","journal-title":"Lancet"},{"key":"R91-20260805","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(18)31715-X","article-title":"Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.","volume":"392","author":"Pilgrim","year":"2018","journal-title":"Lancet"},{"key":"R92-20260805","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1093\/eurheartj\/ehp352","article-title":"Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.","volume":"30","author":"Byrne","year":"2009","journal-title":"Eur Heart J"},{"key":"R93-20260805","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.4244\/EIJY14M11_02","article-title":"Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.","volume":"11","author":"Kufner","year":"2016","journal-title":"EuroIntervention"},{"key":"R94-20260805","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3390\/jpm12091378","article-title":"Ultrathin struts drug-eluting stents: a state-of-the-art review.","volume":"12","author":"Leone","year":"2022","journal-title":"J Pers Med"},{"key":"R95-20260805","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4244\/EIJV8I9A155","article-title":"Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study.","volume":"8","author":"Hamon","year":"2013","journal-title":"EuroIntervention"},{"key":"R96-20260805","doi-asserted-by":"crossref","first-page":"e001441","DOI":"10.1161\/CIRCINTERVENTIONS.114.001441","article-title":"Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.","volume":"8","author":"Windecker","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"R97-20260805","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jcin.2018.04.014","article-title":"Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: 5-year outcomes of the randomized BIOFLOW-II trial.","volume":"11","author":"Lef\u00e8vre","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"R98-20260805","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.4244\/EIJ-D-18-01214","article-title":"BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months.","volume":"15","author":"Saito","year":"2019","journal-title":"EuroIntervention"},{"key":"R99-20260805","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","article-title":"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.","volume":"390","author":"Kandzari","year":"2017","journal-title":"Lancet"},{"key":"R100-20260805","doi-asserted-by":"crossref","first-page":"e003610","DOI":"10.1161\/CIRCINTERVENTIONS.115.003610","article-title":"Randomized comparison of a biodegradable polymer ultrathin strut sirolimus-eluting stent with a biodegradable polymer biolimus-eluting stent in patients treated with percutaneous coronary intervention: the SORT OUT VII trial.","volume":"9","author":"Jensen","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"R101-20260805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2019.02.017","article-title":"Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: rationale and design of the randomized SORT OUT IX trial.","volume":"213","author":"Jensen","year":"2019","journal-title":"Am Heart J"},{"key":"R102-20260805","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jcin.2013.05.013","article-title":"First-in-Human Evaluation of a Bioabsorbable Polymer\u2013Coated Sirolimus-Eluting Stent: Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries).","volume":"6","author":"Ormiston","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"R103-20260805","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4244\/EIJY14M05_03","article-title":"Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial.","volume":"10","author":"Wijns","year":"2015","journal-title":"EuroIntervention"},{"key":"R104-20260805","doi-asserted-by":"crossref","first-page":"e2147","DOI":"10.4244\/EIJ-D-17-00230","article-title":"Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials.","volume":"13","author":"Wijns","year":"2018","journal-title":"EuroIntervention"},{"key":"R105-20260805","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(17)33103-3","article-title":"A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.","volume":"391","author":"De Winter","year":"2018","journal-title":"Lancet"},{"key":"R106-20260805","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(18)32467-X","article-title":"Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.","volume":"393","author":"Zaman","year":"2019","journal-title":"Lancet"},{"key":"R107-20260805","doi-asserted-by":"crossref","first-page":"e010312","DOI":"10.1161\/CIRCINTERVENTIONS.120.010312","article-title":"Prospective multicenter randomized all-comers trial to assess the safety and effectiveness of the ultra-thin strut sirolimus-eluting coronary stent supraflex: two-year outcomes of the TALENT trial.","volume":"14","author":"Gao","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"R108-20260805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40001-021-00595-7","article-title":"Side-branch expansion capacity of contemporary DES platforms.","volume":"26","author":"\u00d6ner","year":"2021","journal-title":"Eur J Med Res"},{"key":"R109-20260805","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.111.026732","article-title":"Polymer-free sirolimus-and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: test Efficacy of Sirolimus-and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial.","volume":"124","author":"Massberg","year":"2011","journal-title":"Circulation"},{"key":"R110-20260805","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jcin.2016.01.009","article-title":"Randomized trial of polymer-free sirolimus-and probucol-eluting stents versus durable polymer zotarolimus-eluting stents: 5-year results of the ISAR-TEST-5 trial.","volume":"9","author":"Kufner","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R111-20260805","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jacc.2020.05.026","article-title":"10-year outcomes from a randomized trial of polymer-free versus durable polymer drug-eluting coronary stents.","volume":"76","author":"Kufner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R112-20260805","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/01.CIR.102.4.399","article-title":"Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans.","volume":"102","author":"Tamai","year":"2000","journal-title":"Circulation"},{"key":"R113-20260805","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0140-6736(08)60415-8","article-title":"A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial.","volume":"371","author":"Ormiston","year":"2008","journal-title":"Lancet"},{"key":"R114-20260805","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.jacc.2011.05.050","article-title":"Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.","volume":"58","author":"Serruys","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R115-20260805","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(12)61765-6","article-title":"Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.","volume":"381","author":"Haude","year":"2013","journal-title":"Lancet"},{"key":"R116-20260805","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcin.2013.07.007","article-title":"A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6-and 12-month clinical and multimodality imaging results.","volume":"7","author":"Verheye","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"R117-20260805","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1161\/CIRCULATIONAHA.110.000901","article-title":"Long-term (>10 years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents.","volume":"125","author":"Nishio","year":"2012","journal-title":"Circulation"},{"key":"R118-20260805","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","article-title":"Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.","volume":"388","author":"Serruys","year":"2016","journal-title":"Lancet"},{"key":"R119-20260805","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.jacc.2017.10.010","article-title":"3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial.","volume":"70","author":"Kereiakes","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R120-20260805","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","article-title":"Everolimus-eluting bioresorbable scaffolds for coronary artery disease.","volume":"373","author":"Ellis","year":"2015","journal-title":"N Engl J Med"},{"key":"R121-20260805","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S0140-6736(18)32283-9","article-title":"Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.","volume":"392","author":"Stone","year":"2018","journal-title":"Lancet"},{"key":"R122-20260805","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jcin.2016.12.020","article-title":"Vasomotor response to nitroglycerine over 5 years follow-up after everolimus-eluting bioresorbable scaffold implantation.","volume":"10","author":"Dudek","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"R123-20260805","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2016.11.033","article-title":"A new novolimus-eluting bioresorbable coronary scaffold: present status and future clinical perspectives.","volume":"227","author":"Nef","year":"2017","journal-title":"Int J Cardiol"},{"key":"R124-20260805","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4244\/EIJY15M02_03","article-title":"An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8\/Xpedition).","volume":"11","author":"Ormiston","year":"2015","journal-title":"EuroIntervention"},{"issue":"Suppl 9","key":"R125-20260805","doi-asserted-by":"crossref","first-page":"S950","DOI":"10.21037\/jtd.2017.07.25","article-title":"The DESolve novolimus bioresorbable Scaffold: from bench to bedside.","volume":"9","author":"Mattesini","year":"2017","journal-title":"J Thorac Dis"},{"key":"R126-20260805","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jcin.2015.12.004","article-title":"Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions.","volume":"9","author":"Abizaid","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R127-20260805","first-page":"1021","article-title":"A multicenter post-marketing evaluation of the elixir DESolve\u00ae Novolimus-eluting bioresorbable coronary scaffold system: first results from the DESolve PMCF study.","volume":"92","author":"Nef","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"R129-20260805","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCINTERVENTIONS.112.971549","article-title":"First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.","volume":"5","author":"Ormiston","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"R130-20260805","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4244\/EIJ-D-17-00306","article-title":"First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial.","volume":"13","author":"Seth","year":"2017","journal-title":"EuroIntervention"},{"key":"R131-20260805","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4244\/EIJ-D-19-00324","article-title":"Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial.","volume":"15","author":"Seth","year":"2019","journal-title":"EuroIntervention"},{"key":"R132-20260805","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/fca-2018-0081","article-title":"Magmaris\u2122 resorbable magnesium scaffold: state-of-art review.","volume":"15","author":"Cerrato","year":"2019","journal-title":"Future Cardiol"},{"key":"R134-20260805","doi-asserted-by":"crossref","first-page":"e004762","DOI":"10.1161\/CIRCINTERVENTIONS.116.004762","article-title":"Comparison of acute thrombogenicity for metallic and polymeric bioabsorbable scaffolds: magmaris versus absorb in a porcine arteriovenous shunt model.","volume":"10","author":"Waksman","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"R135-20260805","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/adhm.201501019","article-title":"Biodegradable metals for cardiovascular stents: from clinical concerns to recent Zn-Alloys.","volume":"5","author":"Bowen","year":"2016","journal-title":"Adv Healthcare Mater"},{"key":"R136-20260805","doi-asserted-by":"crossref","first-page":"100411","DOI":"10.1016\/j.cobme.2022.100411","article-title":"Bioresorbable vascular metallic scaffolds: current status and research trends.","volume":"24","author":"Drelich","year":"2022","journal-title":"Curr Opin Biomed Eng"},{"key":"R138-20260805","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(07)60853-8","article-title":"Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial.","volume":"369","author":"Erbel","year":"2007","journal-title":"Lancet"},{"key":"R139-20260805","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4244\/EIJV8I12A218","article-title":"Bioresorbable drug-eluting magnesium-alloy scaffold: design and feasibility in a porcine coronary model.","volume":"8","author":"Wittchow","year":"2013","journal-title":"EuroIntervention"},{"key":"R140-20260805","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.4244\/EIJ-D-15-00371","article-title":"Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.","volume":"12","author":"Haude","year":"2016","journal-title":"EuroIntervention"},{"key":"R141-20260805","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1093\/eurheartj\/ehw196","article-title":"Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.","volume":"37","author":"Haude","year":"2016","journal-title":"Eur Heart J"},{"key":"R142-20260805","doi-asserted-by":"crossref","first-page":"e1375","DOI":"10.4244\/EIJ-D-18-01000","article-title":"Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.","volume":"15","author":"Haude","year":"2020","journal-title":"EuroIntervention"},{"key":"R143-20260805","article-title":"Coating Techniques and Release Kinetics of Drug-Eluting Stents.","volume":"10","author":"Livingston","year":"2015","journal-title":"J Med Dev"},{"key":"R144-20260805","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R145-20260805","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1161\/01.CIR.0000116202.41966.D4","article-title":"Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent.","volume":"109","author":"Cautious","year":"2004","journal-title":"Circulation"},{"key":"R146-20260805","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.addr.2006.01.016","article-title":"Mechanisms of controlled drug release from drug-eluting stents.","volume":"58","author":"Acharya","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"R147-20260805","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2007.06.025","article-title":"Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution.","volume":"123","author":"Balakrishnan","year":"2007","journal-title":"J Control Release"},{"key":"R148-20260805","doi-asserted-by":"crossref","first-page":"11695","DOI":"10.1021\/acsami.5b01993","article-title":"Controlled slow-release drug-eluting stents for the prevention of coronary restenosis: recent progress and future prospects.","volume":"7","author":"Hu","year":"2015","journal-title":"ACS Appl Mater Interfaces"},{"key":"R149-20260805","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.actbio.2013.12.013","article-title":"Immobilization of heparin\/poly-l-lysine nanoparticles on dopamine-coated surface to create a heparin density gradient for selective direction of platelet and vascular cells behavior.","volume":"10","author":"Liu","year":"2014","journal-title":"Acta Biomater"},{"key":"R150-20260805","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5694\/mja16.00444","article-title":"Coronary stent technology: a narrative review.","volume":"205","author":"Chen","year":"2016","journal-title":"Med J Aust"},{"key":"R151-20260805","first-page":"55","article-title":"Evolution of drug-eluting stent drug elution profile: is a crystalline drug form the ideal solution?","volume":"4","author":"Sangiorgi","year":"2016","journal-title":"Eur Med J"},{"key":"R152-20260805","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s00270-007-9027-4","article-title":"Antirestenotic effects of a novel polymer-coated d-24851 eluting stent. Experimental data in a rabbit iliac artery model.","volume":"30","author":"Lysitsas","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R153-20260805","first-page":"C7","article-title":"Pathophysiology of vascular healing and stent mediated arterial injury.","volume":"4","author":"Nakazawa","year":"2008","journal-title":"EuroIntervention"},{"key":"R154-20260805","doi-asserted-by":"crossref","first-page":"435","DOI":"10.18433\/jpps32053","article-title":"Factors influencing 1st and 2nd generation drug-eluting stent performance: understanding the basic pharmaceutical drug-in-polymer formulation factors contributing to stent thrombosis do we really need to eliminate the polymer?","volume":"24","author":"Srdanovic","year":"2021","journal-title":"J Pharm Pharm Sci"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:15:03Z","timestamp":1785942903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":147,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000705","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}